Find Research Outputs

Search in all content

Filters for Scholarly Output

Search concepts
Selected Filters

Publication Year

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

Author

  • Jorge Eduardo Cortes
2020

A heavy metal baseline score predicts outcome in acute myeloid leukemia

Ohanian, M., Telouk, P., Kornblau, S., Albarede, F., Ruvolo, P., Tidwell, R. S. S., Plesa, A., Kanagal-Shamanna, R., Matera, E. L., Cortes, J., Carson, A. & Dumontet, C., 2020, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journalArticle

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure

Lin, S., Shaik, N., Chan, G., Cortes, J. E. & Ruiz-Garcia, A., Oct 1 2020, In : Cancer Chemotherapy and Pharmacology. 86, 4, p. 451-459 9 p.

Research output: Contribution to journalArticle

Open Access

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Bose, P., Verstovsek, S., Cortes, J. E., Tse, S., Gasior, Y., Jain, N., Jabbour, E. J., Estrov, Z., Alvarado, Y., DiNardo, C. D., Pemmaraju, N., Kornblau, S. M., Kadia, T. M., Daver, N. G., Naqvi, K., Short, N. J., Masarova, L., Villareal, J., Pierce, S. A., Nogueras-Gonzalez, G. & 4 others, Huang, X., Garcia-Manero, G., Kantarjian, H. M. & Ravandi, F., Sep 1 2020, In : Leukemia. 34, 9, p. 2489-2492 4 p.

Research output: Contribution to journalLetter

1 Scopus citations

A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy

Solem, C. T., Bell, T. J., Kwon, Y., Cappelleri, J. C., Johnson, C., Bhattacharyya, H., Hoang, C. J. & Cortes, J. E., Oct 1 2020, In : Cancer. 126, 19, p. 4315-4321 7 p.

Research output: Contribution to journalArticle

Open Access

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

Samra, B., Richard-Carpentier, G., Kadia, T. M., Ravandi, F., Daver, N., DiNardo, C. D., Issa, G. C., Bose, P., Konopleva, M. Y., Yilmaz, M., Ohanian, M., Borthakur, G., Garcia-Manero, G., Pierce, S., Cortes, J. E., Kantarjian, H. & Short, N. J., May 1 2020, In : Blood Cancer Journal. 10, 5, 47.

Research output: Contribution to journalArticle

Open Access

Clinical value of event-free survival in acute myeloid leukemia

Maiti, A., Kantarjian, H. M., Popat, V., Borthakur, G., Garcia-Manero, G., Konopleva, M. Y., DiNardo, C. D., Verstovsek, S., Andreeff, M., Kadia, T. M., Ajufo, H. O., Goswamy, R. V., Blanco, C., Velasquez, M., Daver, N. G., Pemmaraju, N., Pierce, S. R., Wierda, W. G., Kornblau, S. M., Ravandi, F. & 1 others, Cortes, J. E., Apr 28 2020, In : Blood Advances. 4, 8, p. 1690-1699 10 p.

Research output: Contribution to journalArticle

Open Access

Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia

Kolitz, J. E., Strickland, S. A., Cortes, J. E., Hogge, D., Lancet, J. E., Goldberg, S. L., Villa, K. F., Ryan, R. J., Chiarella, M., Louie, A. C., Ritchie, E. K. & Stuart, R. K., Feb 23 2020, In : Leukemia and Lymphoma. 61, 3, p. 631-640 10 p.

Research output: Contribution to journalArticle

Open Access
2 Scopus citations

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

Cortes, J. E., Jiang, Q., Wang, J., Weng, J., Zhu, H., Liu, X., Hochhaus, A., Kim, D. W., Radich, J., Savona, M., Martin-Regueira, P., Sy, O., Gurnani, R. & Saglio, G., Aug 1 2020, In : Leukemia. 34, 8, p. 2064-2073 10 p.

Research output: Contribution to journalArticle

Open Access

Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia

Dao, K. H. T., Gotlib, J., Deininger, M. M. N., Oh, S. T., Cortes, J. E., Collins, R. H., Winton, E. F., Parker, D. R., Lee, H., Schultz, A. R., Stevens, S. S., Brockett, C., Subbiah, N., Press, R. D., Raess, P. W., Cascio, M., Dunlap, J., Chen, Y., Degnin, C., Maxson, J. E. & 4 others, Tognon, C. E., Macey, T., Druker, B. J. & Tyner, J. W., Apr 1 2020, In : Journal of Clinical Oncology. 38, 10, p. 1006-1018 13 p.

Research output: Contribution to journalArticle

3 Scopus citations

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F. & 14 others, Niederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saußele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A. & Hehlmann, R., Apr 2020, In : Leukemia. 34, 4, p. 966-984 19 p.

Research output: Contribution to journalReview article

Open Access
35 Scopus citations

Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies

Mughal, T. I., Pemmaraju, N., Psaila, B., Radich, J., Bose, P., Lion, T., Kiladjian, J. J., Rampal, R., Jain, T., Verstovsek, S., Yacoub, A., Cortes, J. E., Mesa, R., Saglio, G. & van Etten, R. A., 2020, (Accepted/In press) In : Hematological Oncology.

Research output: Contribution to journalArticle

Open Access

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

Abou Dalle, I., Ghorab, A., Patel, K., Wang, X., Hwang, H., Cortes, J., Issa, G. C., Yalniz, F., Sasaki, K., Chihara, D., Price, A., Kadia, T., Pemmaraju, N., Daver, N., DiNardo, C., Ravandi, F., Kantarjian, H. M. & Borthakur, G., May 1 2020, In : Blood Cancer Journal. 10, 5, 48.

Research output: Contribution to journalArticle

Open Access

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

Sasaki, K., Kanagal-Shamanna, R., Montalban-Bravo, G., Assi, R., Jabbour, E., Ravandi, F., Kadia, T., Pierce, S., Takahashi, K., Nogueras Gonzalez, G., Patel, K., Soltysiak, K. A., Cortes, J., Kantarjian, H. M. & Garcia-Manero, G., Feb 15 2020, In : Cancer. 126, 4, p. 765-774 10 p.

Research output: Contribution to journalArticle

6 Scopus citations

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia

Naqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., Jain, N., Takahashi, K., Burger, J., Estrov, Z., Borthakur, G., Pemmaraju, N., Paul, S., Cortes, J. & Kantarjian, H. M., Jan 1 2020, In : Cancer. 126, 1, p. 67-75 9 p.

Research output: Contribution to journalArticle

6 Scopus citations

Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia

Masarova, L., Cortes, J. E., Patel, K. P., O’Brien, S., Nogueras-Gonzalez, G. M., Konopleva, M., Verstovsek, S., Garcia-Manero, G., Ferrajoli, A., Kadia, T. M., Ravandi-Kashani, F., Borthakur, G., DellaSala, S., Estrov, Z., Jabbour, E. J. & Kantarjian, H. M., Apr 1 2020, In : Cancer. 126, 7, p. 1448-1459 12 p.

Research output: Contribution to journalArticle

2 Scopus citations

Long-term results of frontline dasatinib in chronic myeloid leukemia

Maiti, A., Cortes, J. E., Patel, K. P., Masarova, L., Borthakur, G., Ravandi, F., Verstovsek, S., Ferrajoli, A., Estrov, Z., Garcia-Manero, G., Kadia, T. M., Nogueras-González, G. M., Skinner, J., Poku, R., DellaSala, S., Luthra, R., Jabbour, E. J., O’Brien, S. & Kantarjian, H. M., Apr 1 2020, In : Cancer. 126, 7, p. 1502-1511 10 p.

Research output: Contribution to journalArticle

3 Scopus citations

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

Montalban-Bravo, G., Kanagal-Shamanna, R., Class, C. A., Sasaki, K., Ravandi, F., Cortes, J. E., Daver, N., Takahashi, K., Short, N. J., DiNardo, C. D., Jabbour, E., Borthakur, G., Naqvi, K., Issa, G. C., Konopleva, M., Khoury, J. D., Routbort, M., Pierce, S., Do, K. A., Bueso-Ramos, C. & 4 others, Patel, K., Kantarjian, H., Garcia-Manero, G. & Kadia, T. M., Jun 1 2020, In : American Journal of Hematology. 95, 6, p. 612-622 11 p.

Research output: Contribution to journalArticle

2 Scopus citations

Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia

Cortes, J., Podoltsev, N., Kantarjian, H., Borthakur, G., Zeidan, A. M., Stahl, M., Taube, T., Fagan, N., Rajeswari, S. & Uy, G. L., 2020, (Accepted/In press) In : International Journal of Hematology.

Research output: Contribution to journalArticle

Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients

Borthakur, G., Zeng, Z., Cortes, J. E., Chen, H. C., Huang, X., Konopleva, M., Ravandi, F., Kadia, T., Patel, K. P., Daver, N., Kelly, M. A., McQueen, T., Wang, R. Y., Kantarjian, H. & Andreeff, M., 2020, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journalArticle

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Lee, J. H., Faderl, S., Pagel, J. M., Jung, C. W., Yoon, S. S., Pardanani, A. D., Becker, P. S., Lee, H., Choi, J., Lee, K., Kim, M. & Cortes, J. E., May 12 2020, In : Blood Advances. 4, 9, p. 2032-2043 12 p.

Research output: Contribution to journalArticle

Open Access

Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia

Sasaki, K., Kantarjian, H., Wierda, W., Ravandi-Kashani, F., Jorgensen, J., Wang, S. A., Khoury, J., Daver, N., Burger, J., Di Nardo, C. D., Jain, N., Short, N. J., Estrov MD, Z., Konopleva MD, PhD, M., Ohanian DO, M., Garcia-Manero, G., Kadia, T., Alvarado-Valero, Y., Yilmaz, M., Pierce, S. & 5 others, Garris, R., Ingram, A., Cortes, J., OʼBrien, S. & Jabbour, E., Jul 1 2020, In : American Journal of Hematology. 95, 7, p. 734-739 6 p.

Research output: Contribution to journalArticle

Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia

Abaza, Y., Kantarjian, H., Alwash, Y., Borthakur, G., Champlin, R., Kadia, T., Garcia-Manero, G., Daver, N., Ravandi, F., Verstovsek, S., Burger, J., Estrov, Z., Ohanian, M., Lim, M., Pemmaraju, N., Jabbour, E. & Cortes, J., 2020, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journalArticle

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kang, D., Ludwig, E., Jaworowicz, D., Huang, H., Fiedler-Kelly, J., Cortes, J., Ganguly, S., Khaled, S., Krämer, A., Levis, M., Martinelli, G., Perl, A., Russell, N., Abutarif, M., Choi, Y., Mendell, J. & Yin, O., 2020, (Accepted/In press) In : Journal of Clinical Pharmacology.

Research output: Contribution to journalArticle

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Montesinos, P., Roboz, G. J., Bulabois, C. E., Subklewe, M., Platzbecker, U., Ofran, Y., Papayannidis, C., Wierzbowska, A., Shin, H. J., Doronin, V., Deneberg, S., Yeh, S. P., Ozcan, M. A., Knapper, S., Cortes, J., Pollyea, D. A., Ossenkoppele, G., Giralt, S., Döhner, H., Heuser, M. & 5 others, Xiu, L., Singh, I., Huang, F., Larsen, J. S. & Wei, A. H., Jan 1 2020, (Accepted/In press) In : Leukemia.

Research output: Contribution to journalArticle

Open Access
2 Scopus citations

Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia

Ravandi, F., Pierce, S., Garcia-Manero, G., Kadia, T., Jabbour, E., Borthakur, G., DiNardo, C. D., Daver, N., Short, N. J., Alvarado, Y., Cortes, J., Kim, C., Kelsh, M., Katz, A., Williams, R., Yang, Z., Mehta, B. & Kantarjian, H., 2020, (Accepted/In press) In : Clinical Lymphoma, Myeloma and Leukemia.

Research output: Contribution to journalArticle

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review

Cortes, J. E., Candoni, A., Clark, R. E., Leber, B., Montesinos, P., Vyas, P., Zeidan, A. M. & Heuser, M., 2020, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalReview article

Open Access

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Cortes, J. E., Heidel, F. H., Fiedler, W., Smith, B. D., Robak, T., Montesinos, P., Candoni, A., Leber, B., Sekeres, M. A., Pollyea, D. A., Ferdinand, R., Ma, W. W., O'Brien, T., O'Connell, A., Chan, G. & Heuser, M., Jul 14 2020, In : Journal of Hematology and Oncology. 13, 1, 92.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Survivorship in AML–a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

Major, C. K., Kantarjian, H., Sasaki, K., Borthakur, G., Kadia, T., Pemmaraju, N., DiNardo, C., Short, N. J., Daver, N., Jabbour, E., Champlin, R., Garcia-Manero, G., Konopleva, M., Andreeff, M., Kornblau, S., Wierda, W., Pierce, S., Ravandi, F. & Cortes, J., 2020, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

Alfayez, M., Issa, G. C., Patel, K. P., Wang, F., Wang, X., Short, N. J., Cortes, J. E., Kadia, T., Ravandi, F., Pierce, S., Assi, R., Garcia-Manero, G., DiNardo, C. D., Daver, N., Pemmaraju, N., Kantarjian, H. & Borthakur, G., 2020, (Accepted/In press) In : Leukemia.

Research output: Contribution to journalArticle

The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia

Ohanian, M., Kantarjian, H. M., Shoukier, M., Dellasala, S., Musaelyan, A., Nogueras Gonzalez, G. M., Jabbour, E., Abruzzo, L., Verstovsek, S., Borthakur, G., Ravandi, F., Garcia-Manero, G., Tamamyan, G., Champlin, R., Pierce, S., Ferrajoli, A., Kadia, T. & Cortes, J. E., Oct 1 2020, In : American Journal of Hematology. 95, 10, p. 1127-1134 8 p.

Research output: Contribution to journalArticle

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival

Yilmaz, M., Kantarjian, H., Wang, X., Khoury, J. D., Ravandi, F., Jorgensen, J., Short, N. J., Loghavi, S., Cortes, J., Garcia-Manero, G., Kadia, T., Sasaki, K., Konopleva, M., Takahashi, K., Wierda, W., Jain, N., Verstovsek, S., Estrov, Z., Bose, P., Pierce, S. & 3 others, Garris, R., O'Brien, S. & Jabbour, E., Feb 1 2020, In : American Journal of Hematology. 95, 2, p. 144-150 7 p.

Research output: Contribution to journalArticle

3 Scopus citations

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

Hu, B., Lin, X., Lee, H. C., Huang, X., Tidwell, R. S. S., Ahn, K. W., Hu, Z. H., Jabbour, E., Verstovsek, S., Ravandi, F., Garcia-Manero, G., Kharfan-Dabaja, M. A., Hossain, N. M., Marks, D. I., Kamble, R. T., Inamoto, Y., Kindwall-Keller, T., Saad, A., Litzow, M. R., Savani, B. N. & 26 others, Hale, G. A., Bacher, U., Gerds, A. T., Liesveld, J. L., Ustun, C., Olsson, R. F., Daly, A., Grunwald, M. R., Solh, M., DeFilipp, Z., Aljurf, M., Wirk, B., Akpek, G., Nishihori, T., Cerny, J., Seo, S., Hsu, J. W., Champlin, R., de Lima, M., Alyea, E., Popat, U., Sobecks, R., Scott, B. L., Kantarjian, H., Cortes, J. & Saber, W., 2020, In : Leukemia and Lymphoma. p. 1-10 10 p.

Research output: Contribution to journalArticle

1 Scopus citations

Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia–a distinct subtype with favorable prognosis

Yilmaz, M., Kantarjian, H. M., Toruner, G., Yin, C. C., Kanagal-Shamanna, R., Cortes, J. E., Issa, G., Short, N. J., Khoury, J. D., Garcia-Manero, G., Ravandi, F., Kadia, T., Konopleva, M., Wierda, W. G., Jain, N., Estrov, Z., Sasaki, K., Pierce, S., O'Brien, S. M. & Jabbour, E. J., 2020, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

Treatment patterns and deep molecular response in chronic phase–chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study

Cortes, J., Huynh, L., Mendelson, E., Brandt, P., Dalal, D., DerSarkissian, M., Cortina, D., Narkhede, S. & Sheng Duh, M., Jan 2 2020, In : Leukemia and Lymphoma. 61, 1, p. 98-107 10 p.

Research output: Contribution to journalArticle

Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL

Short, N. J., Kantarjian, H., Kanagal-Shamanna, R., Sasaki, K., Ravandi, F., Cortes, J., Konopleva, M., Issa, G. C., Kornblau, S. M., Garcia-Manero, G., Garris, R., Higgins, J., Pratt, G., Williams, L. N., Valentine, C. C., Rivera, V. M., Pritchard, J., Salk, J. J., Radich, J. & Jabbour, E., May 1 2020, In : Blood Cancer Journal. 10, 5, 61.

Research output: Contribution to journalArticle

Open Access

Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias

Maiti, A., Franquiz, M. J., Ravandi, F., Cortes, J. E., Jabbour, E. J., Sasaki, K., Marx, K., Daver, N. G., Kadia, T. M., Konopleva, M. Y., Masarova, L., Borthakur, G., Dinardo, C. D., Naqvi, K., Pierce, S., Kantarjian, H. M. & Short, N. J., 2020, (Accepted/In press) In : Acta Haematologica.

Research output: Contribution to journalArticle

2019

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Jain, P., Kantarjian, H., Boddu, P. C., Nogueras-González, G. M., Verstovsek, S., Garcia-Manero, G., Borthakur, G., Sasaki, K., Kadia, T. M., Sam, P., Ahaneku, H., O’Brien, S., Estrov, Z., Ravandi, F., Jabbour, E. & Cortes, J. E., Mar 26 2019, In : Blood Advances. 3, 6, p. 851-861 11 p.

Research output: Contribution to journalArticle

Open Access
14 Scopus citations

Asciminib in chronic myeloid leukemia after Abl kinase inhibitor failure

Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y. T., Talpaz, M., Hochhaus, A., Coutre, P. L., Ottmann, O., Heinrich, M. C., Steegmann, J. L., Deininger, M. W. N., Janssen, J. J. W. M., Mahon, F. X., Minami, Y., Yeung, D., Ross, D. M. & 10 others, Tallman, M. S., Park, J. H., Druker, B. J., Hynds, D., Duan, Y., Meille, C., Hourcade-Potelleret, F., Vanasse, K. G., Lang, F. & Kim, D. W., Dec 12 2019, In : New England Journal of Medicine. 381, 24, p. 2315-2326 12 p.

Research output: Contribution to journalArticle

23 Scopus citations

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

Pemmaraju, N., Kantarjian, H., Nastoupil, L., Dupuis, M., Zhou, L., Pierce, S., Patel, K. P., Masarova, L., Cortes, J. & Verstovsek, S., May 23 2019, In : Blood. 133, 21, p. 2348-2351 4 p.

Research output: Contribution to journalArticle

15 Scopus citations

Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: A pooled analysis of individual patient data from nine international cohorts

Angenendt, L., Röllig, C., Montesinos, P., Martínez-Cuadrón, D., Barragan, E., García, R., Botella, C., Martínez, P., Ravandi, F., Kadia, T., Kantarjian, H. M., Cortes, J., Juliusson, G., Lazarevic, V., Höglund, M., Lehmann, S., Recher, C., Pigneux, A., Bertoli, S., Dumas, P. Y. & 25 others, Dombret, H., Preudhomme, C., Micol, J. B., Terré, C., Ráčil, Z., Novák, J., Žák, P., Wei, A. H., Tiong, I. S., Wall, M., Estey, E., Shaw, C., Exeler, R., Wagenführ, L., Stölzel, F., Thiede, C., Stelljes, M., Lenz, G., Mikesch, J. H., Serve, H., Ehninger, G., Berdel, W. E., Kramer, M., Krug, U. & Schliemann, C., Oct 10 2019, In : Journal of Clinical Oncology. 37, 29, p. 2632-2642 11 p.

Research output: Contribution to journalArticle

10 Scopus citations

Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia

Cortes, J. E., Jonas, B. A., Graef, T., Luan, Y. & Stein, A. S., Aug 2019, In : Clinical Lymphoma, Myeloma and Leukemia. 19, 8, p. 509-515.e1

Research output: Contribution to journalArticle

Open Access
2 Scopus citations

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

Zhang, H., Savage, S., Schultz, A. R., Bottomly, D., White, L., Segerdell, E., Wilmot, B., McWeeney, S. K., Eide, C. A., Nechiporuk, T., Carlos, A., Henson, R., Lin, C., Searles, R., Ho, H., Lam, Y. L., Sweat, R., Follit, C., Jain, V., Lind, E. & 10 others, Borthakur, G., Garcia-Manero, G., Ravandi, F., Kantarjian, H. M., Cortes, J., Collins, R., Buelow, D. R., Baker, S. D., Druker, B. J. & Tyner, J. W., Dec 1 2019, In : Nature communications. 10, 1, 244.

Research output: Contribution to journalArticle

Open Access
24 Scopus citations
3 Scopus citations

Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/ refractory acute myeloid leukemia: A nonrandomized, open-label, phase II study

Daver, N., Garcia-Manero, G., Basu, S., Boddu, P. C., Alfayez, M., Cortes, J. E., Konopleva, M., Ravandi-Kashani, F., Jabbour, E., Kadia, T., Nogueras-Gonzalez, G. M., Ning, J., Pemmaraju, N., Dinardo, C. D., Andreeff, M., Pierce, S. A., Gordon, T., Kornblau, S. M., Flores, W., Alhamal, Z. & 7 others, Bueso-Ramos, C., Jorgensen, J. L., Patel, K. P., Blando, J., Allison, J. P., Sharma, P. & Kantarjian, H., Mar 1 2019, In : Cancer Discovery. 9, 3, p. 370-383 14 p.

Research output: Contribution to journalArticle

Open Access
74 Scopus citations

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

Abou Dalle, I., Kantarjian, H., Burger, J., Estrov, Z., Ohanian, M., Verstovsek, S., Ravandi, F., Borthakur, G., Garcia-Manero, G., Jabbour, E. & Cortes, J., Nov 1 2019, In : Cancer Medicine. 8, 15, p. 6559-6565 7 p.

Research output: Contribution to journalArticle

Open Access
4 Scopus citations

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)

Lindsley, R. C., Gibson, C. J., Murdock, H. M., Stone, R. M., Cortes, J. E., Uy, G. L., Lin, T. L., Ritchie, E. K., Prebet, T., Ryan, R. J., Faderl, S. & Lancet, J. E., Nov 13 2019, In : Blood. 134, 1, 1 p.

Research output: Contribution to journalArticle

Germline genetic predisposition to myeloid neoplasia from GATA2 gene mutations: Lessons learned from two cases

Dalle, I. A., Bannon, S. A., Patel, K. P., Routbort, M. J., Cortes, J. E., Ferrajoli, A., Kontoyiannis, D. P., Wang, S. A. & DiNardo, C. D., Jan 1 2019, In : JCO Precision Oncology. 3

Research output: Contribution to journalArticle

Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., Fabbiano, F., Erba, H. P., Di Stasi, A., Stuart, R., Olin, R., Kasner, M., Ciceri, F., Chou, W. C., Podoltsev, N., Recher, C. & 11 others, Yokoyama, H., Hosono, N., Yoon, S. S., Lee, J. H., Pardee, T., Fathi, A. T., Liu, C., Hasabou, N., Liu, X., Bahceci, E. & Levis, M. J., Oct 31 2019, In : New England Journal of Medicine. 381, 18, p. 1728-1740 13 p.

Research output: Contribution to journalArticle

88 Scopus citations

Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials

Cortes, J. E., Dombret, H., Merchant, A., Tauchi, T., Dirienzo, C. G., Sleight, B., Zhang, X., Leip, E. P., Shaik, N., Bell, T., Chan, G. & Sekeres, M. A., Jan 1 2019, In : Future Oncology. 15, 31, p. 3531-3545 15 p.

Research output: Contribution to journalArticle

Open Access
6 Scopus citations

Hedgehog signaling inhibitors in solid and hematological cancers

Cortes, J. E., Gutzmer, R., Kieran, M. W. & Solomon, J. A., Jun 2019, In : Cancer Treatment Reviews. 76, p. 41-50 10 p.

Research output: Contribution to journalReview article

Open Access
19 Scopus citations